Filtros de búsqueda

Lista de obras de Bruce E. Sands

A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF.

artículo científico publicado en 2016

A Longitudinal Study of Sexual Function in Women With Newly Diagnosed Inflammatory Bowel Disease

scientific article published on 01 June 2019

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease

scientific article published on 22 December 2019

A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease

artículo científico publicado en 2012

A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease

artículo científico publicado en 2012

A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis

artículo científico publicado en 2008

A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States

artículo científico publicado en 2013

ACG Clinical Guideline: Management of Crohn's Disease in Adults

artículo científico publicado en 2018

Abatacept for Crohn's disease and ulcerative colitis

artículo científico publicado en 2012

Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis.

artículo científico publicado en 2018

Achieving Synergy: Linking an Internet-Based Inflammatory Bowel Disease Cohort to a Community-Based Inception Cohort and Multicentered Cohort in Inflammatory Bowel Disease

artículo científico publicado en 2016

Acute appendicitis following colonoscopy

artículo científico publicado en 2005

Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model

artículo científico publicado en 2011

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

artículo científico publicado en 2007

Anastomotic Ulcers After Ileocolic Resection for Crohn's Disease Are Common and Predict Recurrence

artículo científico publicado en 2019

Anti-TNFα therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis

artículo científico publicado en 2014

Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases

scientific article published on 19 June 2019

Are Gastroenterologists Less Tolerant of Treatment Risks than Patients? Benefit-Risk Preferences in Crohn's Disease Management ⬇️

artículo científico publicado el 1 de octubre de 2010

Babesiosis in a patient on infliximab for Crohn's disease

artículo científico publicado en 2010

Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis

artículo científico publicado en 2012

Body image dissatisfaction in patients with inflammatory bowel disease

artículo científico publicado en 2015

Bridging the gap between host immune response and intestinal dysbiosis in inflammatory bowel disease: does immunoglobulin A mark the spot?

artículo científico publicado en 2015

Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?

artículo científico publicado en 2012

Challenges in designing a national surveillance program for inflammatory bowel disease in the United States

artículo científico publicado en 2014

Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes

scientific article published on 01 October 2019

Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent

artículo científico publicado en 2011

Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study

artículo científico publicado en 2013

Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents ⬇️

artículo científico publicado el 1 de diciembre de 2010

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab

artículo científico publicado en 2009

Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer.

artículo científico publicado en 2016

Comment on 'anti-adhesion therapies and the rule of 3 for rare events'.

artículo científico publicado en 2014

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis

artículo científico publicado en 2020

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease

scientific article published on 13 July 2020

Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development

scientific article published on 26 October 2018

Converging goals of treatment of inflammatory bowel disease from clinical trials and practice

artículo científico publicado en 2014

Correction: ACG Clinical Guideline: Management of Crohn's Disease in Adults

scientific article published on 01 July 2018

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

article

Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease

artículo científico publicado en 2018

Corticosteroid Use in a Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients.

artículo científico publicado en 2016

Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy.

artículo científico

Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease

artículo científico publicado en 2008

Design issues and outcomes in IBD clinical trials

artículo científico publicado en 2005

Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease - an International, Cross-disciplinary Consensus.

artículo científico publicado en 2017

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

artículo científico publicado en 2011

Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

scientific article published on 13 February 2020

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease

scientific article published on 30 May 2018

Development of an index to define overall disease severity in IBD.

artículo científico publicado en 2016

Development of the Crohn's disease digestive damage score, the Lémann score

artículo científico publicado en 2010

Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment

artículo científico publicado en 2012

Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis

artículo científico publicado en 2011

Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease.

artículo científico publicado en 2017

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

artículo científico publicado en 2014

Efficacy and Safety of Extended Induction with Tofacitinib for the Treatment of Ulcerative Colitis

artículo científico publicado en 2020

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study

artículo científico publicado en 2017

Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open

artículo científico publicado en 2019

Efficacy of methotrexate in ulcerative colitis: failure or promise

artículo científico publicado en 2010

Efficient augmentation and relaxation learning for individualized treatment rules using observational data

scientific article published on 01 January 2019

Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study

artículo científico publicado en 2015

Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study

artículo científico

Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments

artículo científico publicado en 2020

Epidemiology of inflammatory bowel disease and overview of pathogenesis

artículo científico publicado en 2009

Erratum: Corrigendum: The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Respo

article

Evaluation of possible inflammatory bowel disease: a survey of Rhode Island physicians

artículo científico publicado en 2012

Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease

artículo científico publicado en 2017

Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1

artículo científico publicado en 2019

Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study

artículo científico publicado en 2010

Functionally defective germline variants of sialic acid acetylesterase in autoimmunity

artículo científico publicado en 2010

Genetics, Genetic Testing, and Biomarkers of Digestive Diseases

artículo científico

Guidelines for immunizations in patients with inflammatory bowel disease

artículo científico publicado en 2004

Gut microbiota density influences host physiology and is shaped by host and microbial factors

artículo científico publicado en 2019

High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy.

artículo científico publicado en 2014

Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study

artículo científico publicado en 2015

IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting

artículo científico publicado en 2011

IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease

scientific article published on 01 January 2020

Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn’s Disease

article

Ileocolic anastomotic inflammation after resection for Crohn's disease indicates disease recurrence: a histopathologic study

artículo científico publicado en 2020

Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease?

artículo científico publicado en 2011

Immunoglobulin A Targets a Unique Subset of the Microbiota in Inflammatory Bowel Disease

artículo científico publicado en 2020

Impact of Hospital Volume on Postoperative Morbidity and Mortality Following a Colectomy for Ulcerative Colitis

artículo científico publicado en 2008

Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial

artículo científico publicado en 2015

Incidence of Crohn's Disease and Ulcerative Colitis in Rhode Island: Report from the Ocean State Crohn's and Colitis Area Registry

artículo científico publicado en 2016

Inflammatory bowel disease microbiotas alter gut CD4 T-cell homeostasis and drive colitis in mice

Infliximab for induction and maintenance therapy for ulcerative colitis

artículo científico publicado en 2005

Infliximab maintenance therapy for fistulizing Crohn's disease

artículo científico publicado en 2004

Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease

scientific article published on 01 April 2005

Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease

artículo científico publicado en 2020

Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers

artículo científico

LRRK2 is involved in the IFN-gamma response and host response to pathogens

artículo científico publicado en 2010

Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply

artículo científico publicado en 2020

Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply

scientific article published on 01 June 2020

Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management

scientific article published on 01 September 2020

Long-term Efficacy of Vedolizumab for Crohn's Disease

artículo científico publicado en 2016

Long-term Efficacy of Vedolizumab for Ulcerative Colitis

artículo científico publicado en 2016

Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies

scientific article published on 11 April 2011

Long-term safety of vedolizumab for inflammatory bowel disease

scientific article published on 02 September 2020

Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study

artículo científico publicado en 2004

Longitudinal Autonomic Nervous System Measures Correlate With Stress and Ulcerative Colitis Disease Activity and Predict Flare

artículo científico publicado en 2020

Luminally-polarized mural and vascular remodeling in ileal strictures of Crohn's Disease.

artículo científico publicado en 2018

Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease

artículo científico publicado en 2020

Mark Warren Babyatsky, MD (June 29, 1959-August 25, 2014).

artículo científico publicado en 2014

Menstrual cycle changes in women with inflammatory bowel disease: a study from the ocean state Crohn's and colitis area registry

artículo científico publicado en 2014

Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis

artículo científico publicado en 2018

Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease

scientific article published on 01 May 2019

Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in Mice.

artículo científico publicado en 2019

Microscopic heterogeneity in ulcerative colitis: implications for microscopic measurement of disease activity

artículo científico publicado en 2019

Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study

scientific article published on 16 December 2019

Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis

artículo científico publicado en 2016

O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohnʼs Disease Refractory to Anti-TFNα

OSCCAR: Ocean State Crohn's and Colitis Area Registry

artículo científico publicado en 2009

Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's disease

artículo científico publicado en 2006

Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease

artículo científico publicado en 2008

Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study

artículo científico publicado en 2018

Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications.

artículo científico publicado en 2008

Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease.

artículo científico publicado en 2006

Possible Association Between Isotretinoin and Inflammatory Bowel Disease

artículo científico publicado en 2006

Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease

artículo científico publicado en 2018

Predictors of Hospital Readmissions for Ulcerative Colitis in the United States: A National Database Study.

artículo científico publicado en 2017

Pregnancy and Neonatal Outcomes after Fetal Exposure To Biologics and Thiopurines among Women with Inflammatory Bowel Disease

artículo científico publicado en 2020

Prevention and treatment of osteoporosis in inflammatory bowel disease

artículo científico publicado en 2006

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

artículo científico publicado en 2010

Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center

artículo científico publicado en 2013

Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease

artículo científico publicado en 2010

Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis

artículo científico publicado en 2020

Reliability and initial validation of the ulcerative colitis endoscopic index of severity

artículo científico publicado en 2013

Reply

Reply to Letter to the Editor of Dr. Lai and Colleagues

artículo científico publicado en 2019

Response to Chamberlin and Borody

scientific article published on 01 January 2019

Response to Chapman and Jones

scientific article published on 01 May 2019

Response to Ribaldone

scientific article published on 01 May 2019

Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases

artículo científico publicado en 2018

Risk factors for colorectal cancer in Crohn's colitis: a case-control study

artículo científico publicado en 2006

Risk factors for radiation exposure in newly diagnosed IBD patients

artículo científico publicado en 2016

Risk of early surgery for Crohn's disease: implications for early treatment strategies

artículo científico publicado en 2003

Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature

artículo científico

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis

artículo científico publicado en 2009

Risks and benefits of infliximab for the treatment of Crohn's disease

artículo científico publicado en 2006

Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial

artículo científico publicado en 2007

SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease

artículo científico publicado en 2014

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

artículo científico publicado en 2020

Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

artículo científico publicado en 2007

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials

scientific article published on 23 November 2018

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

scientific article published on 23 September 2020

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

artículo científico publicado en 2012

Selective leukocyte apheresis for the treatment of inflammatory bowel disease.

artículo científico publicado en 2007

Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease

artículo científico publicado en 2011

Serum Proteome Profiles in Stricturing Crohn's Disease: A Pilot Study

artículo científico publicado en 2015

Sex-Based Differences in Incidence of Inflammatory Bowel Diseases—Pooled Analysis of Population-Based Studies From Western Countries

artículo científico publicado en 2018

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis

scientific article published on 06 January 2019

State of the art: IBD therapy and clinical trials in IBD.

artículo científico publicado en 2005

Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1

scientific article published on 11 June 2020

Testing for Clostridium difficile in patients newly diagnosed with inflammatory bowel disease in a community setting

artículo científico publicado en 2015

The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease

artículo científico publicado en 2018

The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS].

artículo científico publicado en 2015

The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis

scientific article published on 01 September 2019

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

artículo científico publicado en 2010

The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.

artículo científico publicado en 2016

The Whys and Hows of Fourth-Year Inflammatory Bowel Disease Fellowships.

artículo científico publicado en 2017

The day after COVID-19 in IBD: how to go back to 'normal'

artículo científico publicado en 2020

The inflammatory bowel diseases and ambient air pollution: a novel association

artículo científico publicado en 2010

The risk of developing Crohn's disease after an appendectomy: a meta-analysis.

scientific article published on 04 September 2008

The risk of developing Crohn's disease after an appendectomy: a population-based cohort study in Sweden and Denmark

artículo científico publicado en 2007

The role of resilience in irritable bowel syndrome, other chronic gastrointestinal conditions and the general population

scientific article published on 21 August 2020

The safety of vedolizumab for ulcerative colitis and Crohn's disease

artículo científico publicado en 2016

There is Significant Practice Pattern Variability in the Management of the Hospitalized Ulcerative Colitis Patient at a Tertiary Care and IBD Referral Center.

artículo científico publicado en 2016

Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis

scientific article published on 08 May 2019

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

artículo científico publicado en 2017

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

artículo científico publicado en 2017

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies

artículo científico publicado en 2018

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies

artículo científico publicado en 2019

Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists.

artículo científico publicado en 2009

Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC

artículo científico publicado en 2019

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

artículo científico publicado en 2016

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

artículo científico publicado en 2019

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Reply

artículo científico publicado en 2020

Ustekinumab induction and maintenance therapy in refractory Crohn's disease

artículo científico publicado en 2012

Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy

artículo científico publicado en 2020

Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire

artículo científico publicado en 2009

Variation in severity assessment and initial mesalamine dose selection for ulcerative colitis in community practice

artículo científico publicado en 2006

Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States

artículo científico publicado en 2014

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

artículo científico publicado en 2016

Vedolizumab as induction and maintenance therapy for Crohn's disease

artículo científico publicado en 2013

Vedolizumab as induction and maintenance therapy for ulcerative colitis

artículo científico publicado en 2013

Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

artículo científico publicado en 2018

Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3

scientific article published on 01 July 2019

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

artículo científico publicado en 2019

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply

artículo científico publicado en 2020

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme

scientific article published on 09 October 2019

Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study

scientific article published on 23 July 2020

What is the Role of the Inflammatory Bowel Disease Panel in Diagnosis and Treatment?

artículo científico publicado en 2018

When do You Start and When do You Stop Screening for Colon Cancer in Inflammatory Bowel Disease?

artículo científico publicado en 2018

When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations

artículo científico publicado en 2010

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda